Panelists discuss how subcutaneous (SubQ) and intravenous (IV) oncology therapies will continue to coexist, with patient-specific factors guiding delivery method choices, while ongoing innovation and ...
Implementing subcutaneous opioid options in the emergency department significantly reduced reliance on intravenous administration.
When deciding whether to use subcutaneous (SubQ) or intravenous (IV) therapies, clinicians must weigh several clinical and practical factors. One of the first considerations is the type of cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results